Abstract. Dyskeratosis congenita (DKC) is an inherited disease characterized by the triad of mucosal leukoplakia, abnormal skin pigmentation and nail dystrophy, and it usually appears between the ages of 5 and 10 yr. Reports show that 19.5% of DKC patients have short stature (1). A major complication of DKC is progressive development of pancytopenia and there is also an increased incidence of malignancies. The X-linked form accounts for the majority of cases and is caused by mutations in the DKC1 gene. We report a 9 yr old boy, who presented with the triad of DKC, a mutation in the DKC1 gene and short stature, who was treated with human recombinant growth hormone (hGH). This is the first report of a DKC patient treated with hGH.
A 9-yr-old Japanese boy was born to unrelated healthy parents after normal full term pregnancy (38 wk) with a low birth weight of 2048 g. He had mild asphyxia. His parents and his 13-yr-old elder brother are healthy. His mother had experienced one stillbirth and one spontaneous abortion. His father's height is 168 cm (-0.43 SD), that of his mother is 161 cm (+0.62 SD), and that of his brother is 157 cm (-0.23 SD).
The patient had loose stool since the age of 1 yr. When he was 6 yr 5 mo old, leukoplakia was recognized on both sides of his tongue and he was referred to a nearby hospital. Pigmentation of lips, oral mucosa and the inguinal region, and hypoproteinemia (TP: 4.5 g/dl, Alb: 2.7 g/dl) were also present. Since his height was -2.5 SD, hGH treatment was started. During the one-year treatment with hGH, his serum protein level improved but leukoplakia worsened. Therefore, he was referred to our hospital.
On admission, his weight was 18.3 kg (-1.59 SD), his height was 114.7 cm (-1.95 SD), and his head circumference was 48.7 cm (-2.4 SD). Physical examination revealed bilateral tongue leukoplakia, significant nail dystrophy, and hyperpigmentation of the neck, axilla and inguinal region. Although laboratory tests revealed modest hypoproteinemia, there was no evidence of protein losing enteropathy or malabsorption. All other values were within normal ranges (Table 1) . DKC was suspected from these symptoms. The biopsy specimen from the leukoplakia lesion on his tongue did not show any malignant transformation. The findings of the skin biopsy specimen were compatible with skin lesions observed in DKC.
Growth History
Short stature was recognized when the patient was 3 yr old. At 6 yr of age, his height was -2.19 SD (103.1 cm). At 6 yr 6 mo, his height was -2.5 SD (104.7 cm) and his bone age was 4 yr. Table 2 and Table 3 show the results of GH provocation test (insulin and arginine test) and the luteinizing hormone releasing hormone (LHRH) test at that time. The patient was given hGH from 6 yr 8 mo.
After that his leukoplakia seemed to enlarge, so we stopped hGH treatment at 8 yr 6 mo. At 9 yr 4 mo his height was 120 cm (Fig. 1 ). Annual height gain before the hGH treatment was 2.7 cm/yr (-4.0 SD), during the treatment 8 cm/yr (+3 SD) and after the cessation of the treatment 3.2 cm/yr (-2.5 SD).
DKC1 Gene Mutation
After obtaining written informed consent from both the patient and his mother, we performed genetic analysis of the DKC1 gene under permission of the hospital ethical committee. DNA was obtained from blood samples, using standard procedures. Each of the 15 DKC1 exons were amplified by PCR as previously reported (2) . The purified PCR products were directly sequenced using a BigDye Terminator Cycle Sequencing FS Ready Reaction Kit and ABI PRISM 310 Genetic Analyzer (Applied Biosystems Japan, Tokyo). This patient had a C146T mutation in exon 3 of the DKC1 gene (Fig.  2 A) . This resulted in a T49M change in dyskerin. His mother was heterozygous for the mutation. This mutation creates an Nla III site (3); amplification of exon 3 followed by Nla III digestion showed segregation of the mutation with the disease. 
Discussion
The DKC1 gene consists of 15 exons and encodes a protein called dyskerin. There is now indirect evidence that the underlying mechanism of DKC is a failure to maintain the length of telomeres due to injured telomerase. This concurs with the fact that tissues with a high turnover such as epithelia, blood cell, and their derivatives are most predominantly affected, and is supported by a feature of DKC, pre-mature ageing (4).
Mainly missense mutations have been identified in the DKC1 gene (2) in this disorder. Furthermore, a severe variant of dyskeratosis congenita, Hoyeraal-Hreidarsson syndrome (HHS), also caused by a mutation in DKC1, has been identified. HHS is characterized by growth retardation of prenatal onset, microcephaly, cerebellar malformation, mental retardation, aplastic anemia, and immunodeficiency. We identified a C146T point mutation in exon 3 of the DKC1 gene in the patient. This mutation has been previously described in four patients. One was a DKC patient (5) while the others were HHS patients (3, 6) . Our patient showed the DKC triad, but also had HHS characters, such as intrauterine growth restriction (IUGR) and microcephaly. The reason why this mutation causes phenotypical variation is unclear. His mother who was heterogeneous for the mutation did not have the DKC triad; but her hair is getting thin on top and this might be related to the mutation.
Reports of DKC or HHS patients being treated with hGH have not appeared in the literature. In our case, the patient had already undergone regular GH treatment due to short stature. The hormone (0.175 mg/kg/week) seemed effective for height gain, however his tongue lesion worsened. Administration of hGH may accelerate cellular turnover and ageing, since DKC patients cannot maintain telomere length. Moreover, since this d i s o r d e r h a s a h i g h r i s k o f d e v e l o p i n g malignancies, we discontinued hGH therapy. After cessation of hGH treatment, not only leukoplakia but also loose stool seemed to improve but his annual height gain returned to the levels seen before hGH treatment.
In conclusion, short-term hGH treatment was effective at improving short stature in our DKC patient. However, it seemed to aggravate leukoplakia and may increase the risk of malignancy.
